Calidi Biotherapeutics (CLDI) Net Cash Flow (2022 - 2025)

Calidi Biotherapeutics has reported Net Cash Flow for 4 years, with the latest figure at -$4.8 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 162.93% year-over-year to -$4.8 million; the trailing twelve-month figure through Dec 2025 stood at -$4.0 million (down 152.31% YoY), and the FY2025 full-year result was -$4.0 million, down 152.31% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$4.8 million, down from $5.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $8.1 million in Q3 2023, with the low at -$8.2 million in Q4 2023.
• Average Net Cash Flow over 4 years is $225812.5, with a median of $6660.5 recorded in 2022.
• Peak annual rise in Net Cash Flow reached 789.02% in 2023, while the deepest fall reached 3000.35% in 2023.
• Tracing CLDI's Net Cash Flow over 4 years: stood at $282000.0 in 2022, then tumbled by 3000.35% to -$8.2 million in 2023, then surged by 193.87% to $7.7 million in 2024, then plunged by 162.93% to -$4.8 million in 2025.
• The last three Net Cash Flow figures came in at -$4.8 million (Q4 2025), $5.3 million (Q3 2025), and -$5.4 million (Q2 2025), per Business Quant data.

Peer Comparison